Globus Medical Finalizes Nevro Acquisition, Targeting $2.5B Pain Market

Globus Medical has officially completed its acquisition of Nevro Corp., a key player in advanced chronic pain therapies. The move not only adds Nevro’s high-frequency neuromodulation technology to Globus’ arsenal but also opens the door to a $2.5 billion market opportunity in chronic pain management. Dan Scavilla, President and CEO of Globus Medical, shared his enthusiasm: “We are excited to begin the journey of accelerating market penetration of Nevro’s differentiated high-frequency technology and bringing a much-needed treatment option to patients.”

This acquisition marks a strategic expansion for Globus Medical in the musculoskeletal and neuromodulation space, potentially reshaping treatment standards for chronic pain sufferers. Nevro’s common stock was delisted from the NYSE on April 3, 2025, and further transaction details are available via SEC filings. Globus Medical plans to share more about the acquisition’s long-term benefits during its Q1 earnings call in May.